[
    [
        {
            "time": "2023-10-05",
            "original_text": "AbbVie Submits Upadacitinib Applications In US, Europe For Ulcerative Colitis",
            "features": {
                "keywords": [
                    "AbbVie",
                    "Upadacitinib",
                    "Applications",
                    "US",
                    "Europe",
                    "Ulcerative Colitis"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "AbbVie Submits Upadacitinib Applications In US, Europe For Ulcerative Colitis",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-10-05",
            "original_text": "2 Embarrassingly Cheap Dividend Stocks to Buy",
            "features": {
                "keywords": [
                    "Cheap",
                    "Dividend",
                    "Stocks",
                    "Buy"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "general"
                ],
                "causal_factor": "false",
                "causal_impact": "none",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "2 Embarrassingly Cheap Dividend Stocks to Buy",
                "Correlation": 3,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 4,
                "Duration": 3,
                "Entity_Density": 2,
                "Market_Scope": 5,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2023-10-05",
            "original_text": "AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis",
            "features": {
                "keywords": [
                    "AbbVie",
                    "Regulatory",
                    "Applications",
                    "FDA",
                    "EMA",
                    "Upadacitinib",
                    "RINVOQ®",
                    "Treatment",
                    "Adults",
                    "Moderately",
                    "Severely",
                    "Active",
                    "Ulcerative",
                    "Colitis"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 10
            }
        }
    ]
]